GSK provides adjuvants, efficiency boosters which play an essential role in many vaccines.
Frankfurt:
The CEO of GlaxoSmithKline, the world‘s largest vaccine maker, said she was optimistic that the industry could make a COVID-19 vaccination widely available next year.
“I share the optimism that we will have solutions next year. The challenge here is to achieve the scale required, ”GSK CEO Emma Walmsley said at a Confederation of British Industry (CBI) online event on Tuesday.
GSK provides adjuvants, efficacy boosters that play an essential role in many vaccines, in several development alliances for potential future vaccines against the novel coronavirus that has claimed more than a million lives worldwide.
The group’s most advanced project is with French partner Sanofi and the two have said they hope to get their candidate approved next year.
Walmsley stressed that the industry’s unprecedented speed in building up an immunization does not compromise safety because the trials were not smaller than usual and regulators and companies were taking parallel measurements that were previously done consecutively. .
“We’re condensing timelines that can take 10 years into two years. But people should feel very reassured that the way we’re doing it is (due to) a completely different level of collaboration with regulators.” , said the CEO.
“We are putting our funds at risk, governments have put funds at risk so as not to restrict the scale, which is really important in a vaccine trial,” she added.
(Except for the title, this story was not edited by GalacticGaming staff and is posted from a syndicated feed.)
